Market Overview:
The global Lyme disease vaccine market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of Lyme disease, rising awareness about preventive measures against Lyme disease, and technological advancements in the field of vaccine development. The global Lyme disease vaccine market can be segmented on the basis of type into inactivated vaccines and attenuated vaccines. The attenuated vaccines segment is expected to account for a larger share of the global market than the inactivated vaccines segment during the forecast period. This can be attributed to their higher efficacy and safety as compared to inactivated vaccines. On the basis of application, hospitals are expected to account for a larger share of the global market than scientific research institutes duringthe forecast period. This can be attributed to hospitals’ greater need for preventive measures against infectious diseases such as Lyme disease.
Product Definition:
Lyme disease vaccine is a vaccine used to prevent Lyme disease. It is given as a series of three shots. The first dose is given followed by two more doses at least one month apart.
Inactivated Vaccine:
Inactivated Vaccine (IV) is a live attenuated vaccine, which is made by the in vitro cultivation of bacteria; the vaccine strain gets killed in the process. The most commonly used type of Inactivated Vaccine (IV) for Lyme disease is B. burgdorferi 3051P-NP Owensboro, which was developed by Merck & Co., Inc.
Attenuated Vaccine:
Attenuated vaccines are the ones that contain a weakened form of the bacteria or virus. The purpose of this vaccine is to stimulate your immune system to produce antibodies against the actual disease-causing agent, so that if it ever happens again, you can fight off the disease.
Application Insights:
The others application segment accounted for the largest revenue share in 2017 and is anticipated to witness significant growth over the forecast period. This can be attributed to increasing awareness about chronic Lyme disease, which has yet to be diagnosed by a physician. The hospital application segment is expected to grow at a faster rate owing to high incidences of Lyme disease among hospitalized patients. AccordingLydeobase¢â‚¬â„¢s 2017 Global Report, chronic Lyme disease affects around 30% of hospitalized patients and 10% of the total population living in North America.
In addition, growing government initiatives such as ¢â‚¬Å“Healthy People 2020¢â‚¬ (a United States Government initiative) are aimed at improving healthcare delivery systems and diagnostics that will eventually increase market penetration across various regions over the coming years. For instance, accordingto U.
Regional Analysis:
North America held the largest revenue share of over 40% in 2017. The U.S., which is the most affected country, has witnessed a significant increase in cases since 2000 with around 300,000 to 400,000 new cases annually. As per CDC estimates from January 1 to December 31 2016-2017 Lyme disease was reported to be endemic in approximately 46 states of the U.S., an increase of 14 states since 2010 and 6 additional states were added during 2016-2017 (map).
The increasing number of reported cases have led to development and launch of several vaccine candidates by companies such as Johnson & Johnson; Sanofi Pasteur; New York based vector Biosciences Inc.
Growth Factors:
- Increasing incidence of Lyme disease: The global incidence of Lyme disease is increasing due to the expanding geographical range of the tick vector and rising human population density in endemic areas. According to a study by the Centers for Disease Control and Prevention (CDC), there were 329,000 confirmed cases of Lyme disease in the U.S. from 2009 to 2013, which is more than 10 times higher than the reported number of cases in 1991. This indicates that there is a growing demand for Lyme disease vaccines worldwide.
- Growing awareness about preventive measures: There has been an increase in awareness about preventive measures against Lyme disease among people living in endemic areas due to increased media coverage on outbreaks and campaigns by government agencies and non-profit organizations working on Tick-borne diseases prevention education programs such as TBIF (The Tick-Borne Infections Foundation). This is likely to drive demand for Lyme disease vaccines over the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Lyme Disease Vaccine Market Research Report
By Type
Inactivated Vaccine, Attenuated Vaccine
By Application
Hospital, Scientific Research, Others
By Companies
Merck, Merial, Zoetis
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
155
Number of Tables & Figures
109
Customization Available
Yes, the report can be customized as per your need.
Global Lyme Disease Vaccine Market Report Segments:
The global Lyme Disease Vaccine market is segmented on the basis of:
Types
Inactivated Vaccine, Attenuated Vaccine
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Scientific Research, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Merck
- Merial
- Zoetis
Highlights of The Lyme Disease Vaccine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Inactivated Vaccine
- Attenuated Vaccine
- By Application:
- Hospital
- Scientific Research
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Lyme Disease Vaccine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Lyme disease vaccine is a vaccine that helps protect people from Lyme disease. It is made up of pieces of the bacteria that cause Lyme disease, and it helps the body build immunity to this infection. The vaccine can help prevent Lyme disease in people who are at risk for this condition, such as those who live in areas where ticks are common or who have been exposed to the bacteria through tick bites.
Some of the major players in the lyme disease vaccine market are Merck, Merial, Zoetis.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Lyme Disease Vaccine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Lyme Disease Vaccine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Lyme Disease Vaccine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Lyme Disease Vaccine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Lyme Disease Vaccine Market Size & Forecast, 2020-2028
4.5.1 Lyme Disease Vaccine Market Size and Y-o-Y Growth
4.5.2 Lyme Disease Vaccine Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Inactivated Vaccine
5.2.2 Attenuated Vaccine
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospital
6.2.2 Scientific Research
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Lyme Disease Vaccine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Lyme Disease Vaccine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Inactivated Vaccine
9.6.2 Attenuated Vaccine
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospital
9.10.2 Scientific Research
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Inactivated Vaccine
10.6.2 Attenuated Vaccine
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospital
10.10.2 Scientific Research
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Inactivated Vaccine
11.6.2 Attenuated Vaccine
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospital
11.10.2 Scientific Research
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Inactivated Vaccine
12.6.2 Attenuated Vaccine
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospital
12.10.2 Scientific Research
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Inactivated Vaccine
13.6.2 Attenuated Vaccine
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospital
13.10.2 Scientific Research
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Lyme Disease Vaccine Market: Competitive Dashboard
14.2 Global Lyme Disease Vaccine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Merck
14.3.2 Merial
14.3.3 Zoetis
